| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5592826 | Cardiovascular Revascularization Medicine | 2017 | 43 Pages |
Abstract
Despite rapid platelet inhibition provided by cangrelor, newer oral P2Y12 inhibitors such as ticagrelor and prasugrel have comparable clinical outcomes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Medicine
Authors
Peter C. Westman, Michael J. Lipinski, Rebecca Torguson, Ron Waksman,